355 related articles for article (PubMed ID: 32149402)
1. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
[TBL] [Abstract][Full Text] [Related]
2. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
4. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
[TBL] [Abstract][Full Text] [Related]
5. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
6. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
[TBL] [Abstract][Full Text] [Related]
7. Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease.
Uddin MS; Kabir MT; Rahman MH; Alim MA; Rahman MM; Khatkar A; Al Mamun A; Rauf A; Mathew B; Ashraf GM
Curr Pharm Des; 2020; 26(37):4690-4698. PubMed ID: 32250219
[TBL] [Abstract][Full Text] [Related]
8. Gelidiella acerosa protects against Aβ 25-35-induced toxicity and memory impairment in Swiss Albino mice: an in vivo report.
Nisha SA; Devi KP
Pharm Biol; 2017 Dec; 55(1):1423-1435. PubMed ID: 28320234
[TBL] [Abstract][Full Text] [Related]
9. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
10. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
11. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression.
Weinstock M; Luques L; Bejar C; Shoham S
J Neural Transm Suppl; 2006; (70):443-6. PubMed ID: 17017566
[TBL] [Abstract][Full Text] [Related]
12. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
Yun Y; Yang J; Miao Y; Wang X; Sun J
Bioorg Med Chem Lett; 2020 Feb; 30(4):126900. PubMed ID: 31882295
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
[TBL] [Abstract][Full Text] [Related]
15. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
[TBL] [Abstract][Full Text] [Related]
16. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
17. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Youdim MB
Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
[TBL] [Abstract][Full Text] [Related]
18. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
19. Rational Design and Multibiological Profiling of Novel Donepezil-Trolox Hybrids against Alzheimer's Disease, with Cholinergic, Antioxidant, Neuroprotective, and Cognition Enhancing Properties.
Cai P; Fang SQ; Yang XL; Wu JJ; Liu QH; Hong H; Wang XB; Kong LY
ACS Chem Neurosci; 2017 Nov; 8(11):2496-2511. PubMed ID: 28806057
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.
Li F; Wang ZM; Wu JJ; Wang J; Xie SS; Lan JS; Xu W; Kong LY; Wang XB
J Enzyme Inhib Med Chem; 2016; 31(sup3):41-53. PubMed ID: 27384289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
